Introduction
============

The enzyme 17β-hydroxysteroid dehydrogenase type 2 (HSD17B2) plays a vital role in steroid metabolism, including the conversion of the biologically potent factor estradiol into the weakly estrogenic estrone in addition to testosterone and androstenedione [@B1]. There are 14 types of 17β-hydroxysteroid dehydrogenases, and they are named based on their functions, which include the activation of the reduction or oxidation of 17-keto and 17-hydroxy steroids. These processes involve NAD+/NADH or NADP+/NADPH-dependent biological reactions [@B2]. Human HSD17B2 is a protein that consists of 387 amino acids and has a molecular weight of 42,782 Da. From an analysis of its amino acid sequence motifs, HSD17B2 was found to be associated with the membranes of the endoplasmic reticulum [@B3].

Previous studies have shown that HSD17B2 is associated with human anterior pituitary adenomas [@B4], that a low level of expression of HSD17B2 is associated with a poor prognosis in breast cancer [@B5], and that HSD17B2 is associated with an increased risk of sporadic and familial prostate cancer [@B6]. To our knowledge, no previous studies have investigated the relationship between urothelial carcinoma of the urinary tract system and HSD17B2. The aim of this study was to investigate the association between HSD17B2 and prognosis in urothelial carcinoma of the urinary tract system.

Materials and Methods
=====================

Analysis of published transcriptomic datasets
---------------------------------------------

We first analyzed one public transcriptome dataset (GSE31684) that was obtained from the NIH Gene Expression Omnibus. For the data analysis, the raw CEL files available in the Affymetrix HUMAN Genome U133 Plus 2.0 microarray platform were imported into Nexus Expression 3 software (BioDiscovery) to analyze all probe sets without using pre-selection or filtering, as previously described [@B7]-[@B10]. Supervised comparative analyses and functional profiling were performed to identify significantly differentially expressed genes, and special attention was paid to pathways known to be involved in lipid biosynthetic process in Gene Ontology (GO:0008610). Those genes with *P*\< 0.01 and log2-transformed expression fold change \>±0.1 were chosen and the gene with most significant P value and the highest log2-transformed fold-change in expression was selected for further validation. To cross-validate the findings, the transcriptomic data from another dataset (GSE32894), which was generated using an Illumina HumanHT-12 V3.0 expression bead chip, was also analyzed.

Patients and tumor specimens
----------------------------

This study was approved by the Institutional Review Board of the Chi Mei Medical Center (IRB10501005). We enrolled 340 upper urinary tract and 295 urinary bladder formalin-fixed and paraffin-embedded tissue samples that were obtained from patients with urothelial carcinoma between 1996 and 2004. These samples were used to evaluate HSD17B2 using immunohistochemistry. Patients with urothelial carcinoma of the urinary tract received biopsies in the Chi-Mei Medical Center and subsequently underwent a regular treatment and follow-up schedule in the hospital. All patients with urothelial carcinoma of the upper urinary tract received a nephron-ureterectomy, including the resection of the bladder cuff, and a regional lymphadectomy. Patients with superficial urothelial carcinoma of the urinary bladder (pTa and pT1) underwent a transurethral resection of the bladder tumor either with or without the intravesicular application of the bacillus Calmette-Guérin vaccine. For patients with tumor recurrence, a salvage cystectomy was performed.

Radical cystectomy with bilateral pelvic iliac lymphadenectomy was performed for tumors that had invaded the muscle layer of the bladder. Patients with urothelial carcinoma of the urinary bladder with either pT3-4 or node-positive disease received cisplatin-based chemotherapy. Only 29 of 106 patients had a pathologic stage of T3 or higher with/without lymph node metastasis, and these patients received adjuvant chemotherapy for upper tract urothelial malignancies. No patients received neoadjuvant chemotherapy in our study. TNM staging was determined using the most invasive lesion at any multifocality, and we excluded patients with combined urothelial carcinoma of both the upper tract and the urinary bladder.

The mean follow-up durations for patients with upper tract and urinary bladder carcinoma were 44.7 and 30.8 months, respectively. Vascular invasion was defined as the presence of tumor cells inside the endothelium-lined vascular channel within the tumor and surrounding tissues. Perineural invasion was used to describe the spread of cancer into the space surrounding a nerve. The patients were classified into 2 groups; a low mitotic activity group in which the mitotic rate less than 10 per 10 high-power fields and a high mitotic activity group in which the mitotic rate was 10 or more per 10 high-power fields. These methods have also been described in our previous studies [@B7]-[@B10].

Tissues obtained from patients with an initial diagnosis of urothelial carcinoma of the urinary tract with and without metastasis after biopsy were reviewed by two pathologists (C.F. Li and P.I. Liang). The histological classification and stage of each tumor was determined based on hematoxylin- and eosin-stained sections according to the classification system for malignant tumors of the American Joint Committee on Cancer Tumor-Nodes-Metastasis (TNM) [@B11].

Immunohistochemical staining and assessment of HSD17B2
------------------------------------------------------

The tissues, which were previously fixed in formalin and embedded in paraffin, were cut into 4 μm-thick sections. To remove the paraffin wax, the sections were placed in vessels containing fresh xylene, rehydrated in ethanol, and then heated in a microwave. These methods were described in our previous study [@B7]-[@B10]. The tissues were then washed with TRIS buffer and incubated with anti-HSD17B2 monoclonal antibodies (1:100; Abcam).

Statistical analysis
--------------------

We used the Statistical Package for the Social Sciences (SPSS) version 14 for data analysis. Chi-square tests were used to analyze categorical variables, and Fisher\'s exact test was used to analyze contingency variables. These tests were used to determine whether there was a significant association between HSD17B2 expression in urothelial carcinoma tissues and various clinicopathological parameters, including primary tumor (T), nodal metastasis, histological grade, vascular invasion, perineural invasion, and mitotic rate (per 10 high power fields). The endpoints were disease-specific survival and metastatic-free survival. The endpoint results were calculated from the time of diagnosis with urothelial carcinoma to the date of an event (e.g., death or metastasis). Univariate and multivariate analyses were performed to assess the relationships between disease-specific survival or metastatic-free survival and clinicopathological parameters.

Kaplan-Meier curves and estimates of survival data were subsequently used to evaluate the relationship between HSD17B2 expression and survival times. To compare survival times between groups, we used log rank tests to determine whether the survival curves were identical. A P-value of less than 0.05 was considered significant.

Results
=======

Lipid biosynthesis and urothelial carcinoma
-------------------------------------------

Table [1](#T1){ref-type="table"} includes a summary of genes that were differentially expressed in the transcriptome of urothelial carcinoma of the urinary bladder (GSE31684) that are known to be involved in lipid biosynthetic process. These markers were positively associated with cancer invasiveness in urothelial carcinoma of the urinary bladder. Among the genes identified in this analysis, *HSD17B2* was the most significantly associated, in that its expression was lower in T2-4 than in Ta-T1 lesions and had a log2 ratio during progression between these stages of -3.1569 (**Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**, *P*\<0.0001). Additionally, we also tested the expression of HSD17B2 in another GEO dataset (GSE32894) and found that *HSD17B2* expression also decreased as urothelial carcinoma progressed (**Figure [S1](#SM1){ref-type="supplementary-material"}** and **Table [S1](#SM1){ref-type="supplementary-material"}**). Based on these data, we used immunohistochemistry to analyze the association between HSD17B2 and clinicopathological characteristics in patients with urothelial carcinoma of the urinary system.

Patient characteristics and HSD17B2 expression in upper urinary tract urothelial carcinoma
------------------------------------------------------------------------------------------

**Table [2](#T2){ref-type="table"}**shows the correlations between HSD17B2 expression and clinicopathological variables. Among the 340 patients with upper urinary tract urothelial carcinoma, 182 patients were female, and 202 patients were older than 65 years old at the time of diagnosis. The most common tumor location was the ureter, followed by the renal pelvis and both the renal pelvis and the ureter. Most upper urinary tract urothelial carcinomas were present in one location in the urinary system rather than as multifocal tumors. In these patients, noninvasive papillary urothelial carcinoma (Ta) was diagnosed in 89 (26%) patients, 92 (27%) patients had tumors that had invaded the subepithelial connective tissue (T1), and 159 (47%) patients had a tumor with a stage higher than T2. Most patients with upper tract urothelial carcinoma had no nodal metastasis, no vascular invasion, and no perineural invasion, and approximately 51% of the tumors displayed a low mitotic rate. In this study, we found that HSD17B2 expression was not associated with gender, age, tumor location, multifocality, or mitotic rate. A high level of expression of HSD17B2 was correlated with tumor stage in Ta and T1, less nodal metastasis, less vascular invasion, less perineal invasion and a lower histological grade (**Figure [2](#F2){ref-type="fig"}**).

Patient characteristics and HSD17B2 expression in urinary bladder urothelial carcinoma
--------------------------------------------------------------------------------------

There were 295 patients with urinary bladder urothelial carcinoma in the study population. In this group, 216 (73%) patients were male, and 174 (67%) patients were older than 65 years old at the time of diagnosis. There were 84 (28%) papillary noninvasive carcinomas (Ta), 88 (30%) patients in whom the tumor had invaded the subepithelial connective tissue (T1), and 123 (57%) patients with tumors that were staged higher than T2. Most patients with urinary bladder urothelial carcinoma had no nodal metastasis, no vascular invasion, no perineural invasion, and a low rate of mitotic activity. In urinary bladder, urothelial carcinomas, we found that HSD17B2 expression was not associated with gender, age, histological grade, vascular invasion, perineural invasion or mitotic rate. In contrast to upper urinary tract urothelial carcinoma, in urinary bladder urothelial carcinoma, a high level of expression of HSD17B2 was correlated only with Ta and T1 tumor stages and less nodal metastasis.

Prognosis in upper urinary tract urothelial carcinoma
-----------------------------------------------------

**Table [3](#T3){ref-type="table"}**shows the results of the univariate and multivariate analyses for disease-specific and metastasis-free survival in upper urinary tract urothelial carcinoma. In the univariate analyses for disease-specific survival, the statistically significant parameters included tumor location, multifocality, primary tumor, nodal metastasis, histological grade, vascular invasion, perineal invasion and HSD17B2 expression. After multivariate analysis, only nodal metastasis, histological grade, perineural invasion and HSD17B2 expression were significantly associated with disease-specific survival. The multivariate analysis of metastasis-free survival revealed associations with multifocality, nodal metastasis, histological grade, and HSD17B2 expression. Moreover, of the clinicopathological parameters that affected outcomes in urothelial carcinoma, a high expression level of HSD17B2 was associated with better outcomes in upper urinary tract urothelial carcinoma.

Prognosis in urinary bladder urothelial carcinoma
-------------------------------------------------

**Table [4](#T4){ref-type="table"}**shows the results of the univariate and multivariate analyses used to analyze associations with disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma. In the univariate analyses, many parameters, including primary tumor (T), nodal metastasis, histological grade, vascular invasion, perineal invasion, mitotic rate and HSD17B2 expression, had significant prognostic value for predicting both disease-specific survival and metastasis-free survival. After the multivariate analysis, only primary tumor (T), mitotic rate and HSD17B2 expression were significantly associated with prognosis.

In addition to these clinicopathological parameters, a high level of HSD17B2 expression was associated with better outcomes in urinary bladder urothelial carcinoma. In Figure [3](#F3){ref-type="fig"}, the results of log-rank tests show that that a high level of expression of HSD17B2 was a novel predictive marker of a better prognosis, including disease-specific survival and metastasis-free survival, in urothelial carcinoma of the urinary system.

Discussion
==========

Evaluating the level of expression of HSD17B2 could significantly impact outcome predictions in urinary tract urothelial carcinoma. This is the first study to explore the relationship between HSD17B2 and urothelial carcinoma of the urinary tract system. Although adjuvant chemotherapy provides an overall survival benefit in patients with macroscopic perivesicular tissue invasion [@B12], the prognosis for these patients when they have urinary tract urothelial carcinoma remains poor [@B13]. A previous study focused on identifying markers of poor prognosis. Ma et al. [@B7] showed that a higher level of expression of SPOCK1 was associated with adverse outcomes in urothelial carcinoma. Chang et al. [@B8] found that a member of the melanoma-associated antigen gene (MAGE) family, NDN, predicted a poor prognosis in patients with urothelial carcinomas. Lee at al. [@B9] showed that overexpressing colony-stimulating factor 2 advanced the disease status and was associated with a poor prognosis in patients with urothelial carcinoma, suggesting that colony-stimulating factor 2 may be an important prognostic indicator and a potential therapeutic target. Our study shows that HSD17B2 expression is positively correlated with prognosis in urothelial carcinoma of the urinary tract system.

HSD17B2 protects tissues from excessive steroid activity and is abundantly expressed in a variety of human tissues, such as the placenta, uterus, and liver and the gastrointestinal and urinary tracts [@B14]. In one study of cancer cell lines, while 17β-Hydroxysteroid dehydrogenases type 1 expression was higher in T47D breast cancer and JEG3 choriocarcinoma cells, HSD17B2 activity was low in both of these lines [@B15].

A previous study investigated the role of HSD17B2 in colon cancer and found that the expression of HSD17B2 was downregulated in colon cancer. A higher percentage of female patients with colon cancer than male patients with colon cancer overexpressed HSD17B2. Additionally, the 5-year overall survival rate in female patients with low expression levels of HSD17B2 was 54%, and none of the female patients with HSD17B2 overexpression survived. The authors suggested that the HSD17B2 mRNA is an independent marker of a poor prognosis in female patients with colon cancer, but there was no association between HSD17B2 and prognosis in male patients with colon cancer [@B16]. In contrast to colon cancer, our study demonstrated that a high level of expression of HSD17B2 is a favorable prognostic indicator in urothelial carcinoma and that this relationship was not associated with gender. It is important to identify the different and sophisticated regulatory mechanisms that are affected by HSD17B2 to drive tumorigenesis in different types of tumors.

Previous studies have shown that HSD17B2 has been detected in both benign and malignant ovarian tumor tissues, but its activity level varies between samples [@B17]-[@B19]. In cell line studies, both the enzymatic activity and mRNA expression of HSD17B2 have been observed in epithelial cancer cells. HSD17B2 has both anti-estrogenic and anti-androgenic functions. Because different receptors for estrogen, androgen and progesterone have been detected in ovarian epithelial tumors, the role of HSD17B2 in the tumorigenesis of ovarian cancer remains controversial [@B20].

HSD17B2 can convert estradiol to the less active estrone. In normal breast tissue, the oxidative pathway (from estradiol to estrone) predominates in epithelial and stromal cells. However, in breast cancer cells, the reductive pathway is dominant [@B21]. For breast cancer cells to maintain an appropriate concentration of estradiol, the expression of HSD17B2 must therefore be reduced. However, the expression of 17β-hydroxysteroid dehydrogenase type 12 was found to be high [@B22]. In that study, because only a small number of cases had breast cancer, no significant association was found between HSD17B2 expression and other clinicopathological parameters [@B19]. Another study demonstrated that a high level of expression of HSD17B2 decreased the risk of later recurrence in patients with estrogen receptor-positive breast cancer [@B23]. In addition to estrogen receptor-positive breast cancer, our study also revealed a trend toward improved overall survival in urothelial carcinoma patients with high expression levels of HSD17B2.

Steroid hormones, including HSD17B2, play important roles in the development of breast cancer [@B22], ovarian cancer [@B18], endometrial cancer and prostate cancer [@B24]. The distribution and function of steroid hormone receptors in these tumor cells may have potential effects on tumor progression. The relationships between steroid hormone expression and the clinical stages of urothelial carcinoma of the urinary tract system remain unclear. Our results suggest that HSD17B2 is involved in the regulation of hormone balance in urothelial carcinoma of the urinary tract system and that this factor has a substantial impact on tumor growth and development. We propose that not only HSD17B2, but many other enzymes that are required for steroid biosynthesis and metabolism and therefore crucial for tumor growth, could be inhibited to explore their therapeutic potential.

In conclusion, our study revealed that HSD17B2 plays an important role in urothelial carcinoma of the urinary tract. High expression of HSD17B2 was associated with better clinicopathological parameters and was also an independent prognostic indicator. Hence, future studies aimed at determining the regulatory mechanism underlying the activity of HSD17B2 in urothelial carcinoma and developing this marker as a potential novel therapeutic target for cancer treatment are warranted.
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![An analysis of gene expression in urothelial carcinoma of the urinary tract system was performed using a published transcriptomic dataset (GSE31684). The clustering analysis focused on genes involved in regulating steroid metabolism. The results revealed that 17β-hydroxysteroid dehydrogenase type 2 was the most significantly down-regulated gene and that its expression was associated with a decrease in pT status. The pT statuses of the tissue specimens obtained from different tumors are shown on top of the heat map, and the upregulation or downregulation of the genes is illustrated as a spectrum of red and green brightness, respectively. Unaltered genes are shown as black.](jcav07p2221g001){#F1}

![HSD17B2 immunostaining of representative tissue sections revealed a progressive stepwise decrease in the expression of HSD17B2 in non-tumoral urothelium and in (A) non-invasive (B) and infiltrating urothelial carcinoma (C) (X400).](jcav07p2221g002){#F2}

![A survival analysis was plotted using Kaplan-Meier curves. Using a log-rank test, we found that a high level of HSD17B2 expression predicted favorable disease-specific survival in urothelial carcinoma of the upper tract (A) and urinary bladder (C) and favorable metastasis-free survival in urothelial carcinoma of the upper tract (B) and urinary bladder (D).](jcav07p2221g003){#F3}

###### 

Summary of differentially expressed genes associated with lipid biosynthetic process (GO:0008610) that showed positive associations with cancer invasiveness in the transcriptome of urothelial carcinoma of the urinary bladder (GSE31684).

  Probe          Comparing T2-4 to Ta-T1   Gene Symbol   Gene Title      Molecular Function                                                                               
  -------------- ------------------------- ------------- --------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  204818_at      -3.1569                   \<0.0001      ***HSD17B2***   hydroxysteroid (17-beta) dehydrogenase 2                                                         estradiol 17-beta-dehydrogenase activity, oxidoreductase activity
  204607_at      -2.4778                   \<0.0001      ***HMGCS2***    3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial)                                 hydroxymethylglutaryl-CoA synthase activity, transferase activity
  226064_s\_at   -1.0777                   \<0.0001      ***DGAT2***     diacylglycerol O-acyltransferase homolog 2 (mouse)                                               acyltransferase activity, diacylglycerol O-acyltransferase activity, transferase activity
  241954_at      -0.8037                   0.0010        ***FDFT1***     Farnesyl-diphosphate farnesyltransferase 1                                                       catalytic activity, farnesyl-diphosphate farnesyltransferase activity, magnesium ion binding, oxidoreductase activity, protein binding, transferase activity
  214917_at      -0.6561                   0.0070        ***PRKAA1***    protein kinase; AMP-activated; alpha 1 catalytic subunit                                         ATP binding, cAMP-dependent protein kinase activity, kinase activity, magnesium ion binding, metal ion binding, nucleotide binding, protein kinase activity, protein serine/threonine kinase activity, transferase activity
  240110_at      -0.6423                   0.0001        ***HMGCS2***    3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial)                                 hydroxymethylglutaryl-CoA synthase activity, transferase activity
  208647_at      -0.5354                   0.0097        ***FDFT1***     farnesyl-diphosphate farnesyltransferase 1                                                       catalytic activity, farnesyl-diphosphate farnesyltransferase activity, magnesium ion binding, oxidoreductase activity, protein binding, transferase activity
  201834_at      -0.5118                   \<0.0001      ***PRKAB1***    protein kinase; AMP-activated; beta 1 non-catalytic subunit                                      hydrolase activity; hydrolyzing O-glycosyl compounds, protein binding
  229958_at      -0.4394                   0.0001        ***CLN8***      ceroid-lipofuscinosis; neuronal 8 (epilepsy; progressive with mental retardation)                
  237208_at      -0.4029                   0.0022        ***WDR61***     WD repeat domain 61                                                                              catalytic activity, isomerase activity, triose-phosphate isomerase activity
  232428_at      -0.2564                   0.0015        ***MOGAT2***    monoacylglycerol O-acyltransferase 2                                                             2-acylglycerol O-acyltransferase activity, acetyltransferase activity, acyltransferase activity, transferase activity
  208131_s\_at   1.6423                    \<0.0001      ***PTGIS***     prostaglandin I2 (prostacyclin) synthase                                                         heme binding, iron ion binding, isomerase activity, metal ion binding, monooxygenase activity, prostaglandin-I synthase activity
  224901_at      1.3137                    \<0.0001      ***SCD5***      stearoyl-CoA desaturase 5                                                                        iron ion binding, oxidoreductase activity, oxidoreductase activity; acting on paired donors; with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water, stearoyl-CoA 9-desaturase activity
  215813_s\_at   0.8976                    0.0003        ***PTGS1***     prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)            iron ion binding, metal ion binding, oxidoreductase activity, oxidoreductase activity; acting on single donors with incorporation of molecular oxygen; incorporation of two atoms of oxygen, peroxidase activity, prostaglandin-endoperoxide synthase activity
  208881_x\_at   0.8359                    0.0007        ***IDI1***      isopentenyl-diphosphate delta isomerase 1                                                        hydrolase activity, isomerase activity, isopentenyl-diphosphate delta-isomerase activity, magnesium ion binding, metal ion binding
  238669_at      0.8155                    0.001         ***PTGS1***     prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)            iron ion binding, metal ion binding, oxidoreductase activity, oxidoreductase activity; acting on single donors with incorporation of molecular oxygen; incorporation of two atoms of oxygen, peroxidase activity, prostaglandin-endoperoxide synthase activity
  205128_x\_at   0.8019                    0.0036        ***PTGS1***     prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)            iron ion binding, metal ion binding, oxidoreductase activity, oxidoreductase activity; acting on single donors with incorporation of molecular oxygen; incorporation of two atoms of oxygen, peroxidase activity, prostaglandin-endoperoxide synthase activity
  208788_at      0.6671                    0.0043        ***ELOVL5***    ELOVL family member 5; elongation of long chain fatty acids (FEN1/Elo2; SUR4/Elo3-like; yeast)   
  219532_at      0.6276                    \<0.0001      ***ELOVL4***    elongation of very long chain fatty acids (FEN1/Elo2; SUR4/Elo3; yeast)-like 4                   G-protein coupled photoreceptor activity
  202314_at      0.6199                    0.0017        ***CYP51A1***   cytochrome P450; family 51; subfamily A; polypeptide 1                                           heme binding, iron ion binding, metal ion binding, monooxygenase activity, oxidoreductase activity, protein binding, sterol 14-demethylase activity
  205822_s\_at   0.4701                    0.0099        ***HMGCS1***    3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)                                       hydroxymethylglutaryl-CoA synthase activity, transferase activity
  211892_s\_at   0.2027                    0.0004        ***PTGIS***     prostaglandin I2 (prostacyclin) synthase                                                         heme binding, iron ion binding, isomerase activity, metal ion binding, monooxygenase activity, prostaglandin-I synthase activity
  211019_s\_at   0.1844                    0.0058        ***LSS***       lanosterol synthase (2;3-oxidosqualene-lanosterol cyclase)                                       catalytic activity, isomerase activity, lanosterol synthase activity, lyase activity

\#: Meta., distal metastasis developed during follow-up; Non-Meta.: no metastasis developed.

###### 

Correlations between RNF128 Expression and other important clinicopathological parameters in urothelial carcinomas.

  Parameter                                 Category        Upper Urinary Tract Urothelial Carcinoma   Urinary Bladder Urothelial Carcinoma                                       
  ----------------------------------------- --------------- ------------------------------------------ -------------------------------------- ----- ----------- ----- ----- ----- -----------
  Gender                                    Male            158                                        79                                     79    1.000       216   105   111   0.489
  Female                                    182             91                                         91                                           79          42    37          
  Age (years)                               \< 65           138                                        69                                     69    1.000       121   67    54    0.112
  ≥ 65                                      202             101                                        101                                          174         80    94          
  Tumor location                            Renal pelvis    141                                        61                                     80    0.093       \-    \-    \-    \-
  Ureter                                    150             84                                         66                                           \-          \-    \-    \-    
  Renal pelvis & ureter                     49              25                                         24                                           \-          \-    \-    \-    
  Multifocality                             Single          278                                        138                                    140   0.779       \-    \-    \-    \-
  Multifocal                                62              32                                         30                                           \-          \-    \-    \-    
  Primary tumor (T)                         Ta              89                                         59                                     30    \<0.001\*   84    52    32    \<0.001\*
  T1                                        92              63                                         29                                           88          52    36          
  T2-T4                                     159             48                                         111                                          123         43    80          
  Nodal metastasis                          Negative (N0)   312                                        163                                    149   0.006\*     266   141   125   0.001\*
  Positive (N1-N3)                          28              7                                          21                                           29          6     23          
  Histological grade                        Low grade       56                                         60                                     38    0.008\*     56    31    25    0.358
  High grade                                284             110                                        132                                          239         116   123         
  Vascular invasion                         Absent          234                                        141                                    93    \<0.001\*   246   128   118   0.090
  Present                                   106             29                                         77                                           49          19    30          
  Perineural invasion                       Absent          321                                        167                                    154   0.002\*     275   141   134   0.066
  Present                                   19              3                                          16                                           20          6     14          
  Mitotic rate (per 10 high-power fields)   \< 10           173                                        94                                     79    0.104       139   76    63    0.116
  \>= 10                                    167             76                                         91                                           156         71    85          

\* Statistically significant.

###### 

Univariate log-rank and multivariate analyses of Disease-specific and Metastasis-free Survival in upper urinary tract urothelial carcinoma.

  Parameter                                 Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                         
  ----------------------------------------- --------------- ---------- --------------------------- -------------------------- -------------- ---- ----------- ---- ------------ -------------- ---- -----------
  Gender                                    Male            158        28                          0.8286                     \-             \-   \-          32   0.7904       \-             \-   \-
  Female                                    182             33                                     \-                         \-             \-   38               \-           \-             \-   
  Age (years)                               \< 65           138        26                          0.9943                     \-             \-   \-          30   0.8470       \-             \-   \-
  ≥ 65                                      202             35                                     \-                         \-             \-   40               \-           \-             \-   
  Tumor side                                Right           177        34                          0.7366                     \-             \-   \-          38   0.3074       \-             \-   \-
  Left                                      154             26                                     \-                         \-             \-   32               \-           \-             \-   
  Bilateral                                 9               1                                      \-                         \-             \-   0                \-           \-             \-   
  Tumor location                            Renal pelvis    141        24                          0.0079\*                   1              \-   0.972       31   0.0659       \-             \-   \-
  Ureter                                    150             22                                     0.990                      0.273-3.587         25               \-           \-             \-   
  Renal pelvis & ureter                     49              15                                     0.917                      0.226-3.732         14               \-           \-             \-   
  Multifocality                             Single          273        48                          0.0026\*                   1              \-   0.107       52   0.0127\*     1              \-   0.002\*
  Multifocal                                62              18                                     2.806                      0.800-9.840         18               2.372        1.367-4.117         
  Primary tumor (T)                         Ta              89         2                           \<0.0001\*                 1              \-   0.151       4    \<0.0001\*   1              \-   0.090
  T1                                        92              9                                      4.191                      0.885-19.853        15               3.401        1.107-10.456        
  T2-T4                                     159             50                                     4.376                      0.963-19.898        51               2.312        0.727-7.350         
  Nodal metastasis                          Negative (N0)   312        42                          \<0.0001\*                 1              \-   \<0.001\*   55   \<0.0001\*   1              \-   \<0.001\*
  Positive (N1-N3)                          28              19                                     6.094                      3.285-11.306        15               3.309        1.778-6.155         
  Histological grade                        Low grade       56         4                           0.0215\*                   1              \-   0.004\*     3    0.0027\*     1              \-   0.036\*
  High grade                                284             57                                     4.337                      1.597-11.776        67               2.326        1.055-5.128         
  Vascular invasion                         Absent          234        24                          \<0.0001\*                 1              \-   0.148       26   \<0.0001\*   1              \-   0.004\*
  Present                                   106             37                                     1.568                      0.853-2.881         44               2.395        1.325-4.329         
  Perineural invasion                       Absent          321        50                          \<0.0001\*                 1              \-   0.001\*     61   \<0.0001\*   1              \-   0.027\*
  Present                                   19              11                                     3.625                      1.723-7.626         9                2.312        1.101-4.854         
  Mitotic rate (per 10 high-power fields)   \< 10           173        27                          0.167                      \-             \-               30   0.0823       \-             \-   
  \>= 10                                    167             34                                     \-                         \-                  40               \-           \-                  
  HSD17B2 expression                        High            170        15                          \<0.0001\*                 1              \-   0.031\*     17   \<0.0001\*   1              \-   0.003\*
  Low                                       170             46                                     2.027                      1.066-3.856         53               2.438        1.2352-4.395        

\* Statistically significant.

###### 

Univariate log-rank and multivariate analyses of Disease-specific and Metastasis-free Survival in urinary bladder urothelial carcinoma.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter\                                    Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                                           
  --------------------------------------------- --------------- ---------- --------------------------- -------------------------- ------------------- ---- ------------- ---- ---------------- ------------------ ------- ---------------
  **Gender**                                    Male            216        41                          0.4446                     \-                  \-   \-            60   0.2720           \-                 \-      \-

  Female                                        79              11                                     \-                         \-                  \-   16                 \-               \-                 \-      

  **Age (years)**                               \< 65           121        17                          0.1136                     \-                  \-   \-            31   0.6875           \-                 \-      \-

  ≥ 65                                          174             35                                     \-                         \-                  \-   45                 \-               \-                 \-      

  **Primary tumor (T)**                         Ta              84         1                           **\<0.0001\***             **1**               \-   **0.001\***   4    **\<0.0001\***   **1**              \-      **0.013\***

  T1                                            88              9                                      **6.498**                  **0.670-63.037**         23                 **5.134**        **1.460-18.051**           

  T2-T4                                         123             42                                     **23.551**                 **2.454-226.044**        49                 **6.852**        **1.905-24.648**           

  **Nodal metastasis**                          Negative (N0)   266        41                          **0.0002\***               1                   \-   0.971         61   **\<0.0001\***   1                  \-      0.239

  Positive (N1-N3)                              29              11                                     0.987                      0.483-2.018              15                 1.462            0.777-2.750                

  **Histological grade**                        Low grade       56         2                           **0.0013\***               1                   \-   0.856         5    **0.0007\***     1                  \-      0.805

  High grade                                    239             50                                     0.860                      0.169-4.368              71                 0.870            0.287-2.639                

  **Vascular invasion**                         Absent          246        37                          **0.0024\***               1                   \-   0.415         54   **0.0001\***     1                  \-      0.449

  Present                                       49              15                                     0.748                      0.372-1.503              22                 1.269            0.686-2.347                

  **Perineural invasion**                       Absent          275        44                          **0.0001\***               1                   \-   0.067         66   **0.0007\***     1                  \-      0.326

  Present                                       20              8                                      2.165                      0.948-4.944              10                 1.442            0.694-2.994                

  **Mitotic rate (per 10 high-power fields)**   \< 10           139        12                          **\<0.0001\***             **1**               \-   **0.023\***   23   **\<0.0001\***   **1**              **-**   **0.032\***

  \>= 10                                        156             40                                     **2.169**                  1.113-4.229              53                 **1.756**        **1.050-2.36**             

  **HSD17B2 expression**                        High            147        11                          **\<0.0001\***             **1**               \-   **0.001\***   22   **\<0.0001\***   **1**              **-**   **\<0.001\***

  Low                                           148             41                                     **3.288**                  1.630-6.634              54                 **2.689**        **1.585-4.562**            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Statistically significant.
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